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Background: Daily throughout 2011, about 900 new HIV infections occurred in children and 630 children died as a
result of AIDS-related complications worldwide. Late diagnosis, mortality trends, causes of and risk factors for death
were evaluated in vertically HIV-infected children.
Methods: A retrospective 11-year study was conducted with Brazilian vertically HIV-infected children and adolescents
using patients’ charts. Medical records, death certificates and the Ministry of Health’s mortality database were verified
for mortality and cause of death. Diagnoses were made according to the CDC Revised Classification System for HIV
infection.
Results: Of 177 patients included, 97 were female (54.8%). Median age at admission was 30 months (IQR: 5–72
months). Median follow-up was 5 years (IQR: 2–8 years). After 11 years, 132 (74,6%) patients continued in follow-up, 11
(6.2%) had been transferred and 8 (4.5%) were lost to follow-up. Twenty-six deaths occurred (14,7%), the majority
(16/26; 61.5%) in children <3 years of age. Death cases decreased over time and the distribution of deaths was
homogenous over the years of evaluation. In 17/26 (65.4%) of the children who died, diagnosis had been made
as the result of their becoming ill. Beginning antiretroviral therapy before 6 months of age was associated with
being alive (OR = 2.86; 95% CI: 1.12–7.25; p = 0.027). The principal causes of death were severe bacterial infections
(57%) and opportunistic infections (33.3%).
Conclusions: In most of the HIV-infected children, diagnosis was late, increasing the risk of progression to AIDS and
death due to delayed treatment. The mortality trend was constant, decreasing in the final two years of the study.
Bacterial infections remain as the major cause of death. Improvements in prenatal care and pediatric monitoring
are mandatory.
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Since 1996, when highly active antiretroviral therapy
(HAART) began to be implemented and protease inhibi-
tors were first introduced, a significant reduction has oc-
curred in the morbidity and mortality associated with
the human immunodeficiency virus (HIV) in adults and
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infected adults and children [5-9].
Nineteen years after the first study showed the effi-
cacy of zidovudine in reducing the vertical transmission
of HIV, failure to provide prenatal prevention continues
in various resource-limited countries including Brazil
[10-14]. Delays in the diagnosis of hundreds of HIV-
infected children have increased their risk of progression
to AIDS and death due to a lack of timely treatment [15].
A study comparing mortality in children with AIDS in the
post-HAART era between developed and resource-limited
countries showed the post-HAART mortality rates to beentral. This is an Open Access article distributed under the terms of the Creative
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scarce [16].
Daily throughout 2011, an average of 900 new HIV in-
fections occurred in children and 630 children died as a
result of AIDS-related complications worldwide, with
the majority of these infections in the pediatric popula-
tion being associated with vertical HIV transmission
[17]. For more than ten years, efforts have been made to
implement a “test and treat” strategy in pediatric HIV
care [13]. The randomized clinical study, CHER (the
Children with HIV Early Retroviral Therapy Trial), on
antiretroviral therapy strategies in South Africa showed
that early diagnosis and prompt antiretroviral therapy
in infants with vertically-transmitted HIV infection re-
duced early mortality by 76% and progression to AIDS
by 75% compared to treatment in accordance with the
consensuses [18].
According to the World Health Organization (WHO)’s
recommendations [19], any HIV-infected child under
two years of age should be treated with antiretroviral
therapy as soon as possible, even when no symptoms are
present and irrespective of CD4+ T-cell count. HIV-
infected infants present clinical signs in the first year of
life and without effective treatment one-third will die be-
fore completing one year of life and half will die before
their second birthday [19].
Early diagnosis of the HIV infection will determine the
prognosis both of children born to seropositive mothers
whose condition was detected prior to or during preg-
nancy or delivery and of those with nonspecific constitu-
tional symptoms, but who require recurrent medical
care [4,13,14]. Children diagnosed as HIV-infected have
a higher rate of infection and these infections are always
more severe. Monitoring these children is important in
order to be able to instruct the families on the severity
of AIDS and its consequences, to provide better care to
improve their quality of life and to increase their survival
time [20].
A study conducted with HIV-infected children in
Africa and in Brazil showed that the most important
predictors of mortality in untreated children were
CD4+ T-cell count, low weight for age and hemoglobin
levels [21]. A cohort study of HIV-infected children and
adolescents in Belo Horizonte, Brazil concluded that
the most important predictive factors of progression to
AIDS were advanced stages of the disease, CD4+ per-
centage < 15% and HIV viral load >5 log10 [22]. The ob-
jective of the present study was to evaluate the risk
factors for progression to death, late diagnosis, causes
of death and mortality trends in a cohort of vertically
HIV-infected children and adolescents receiving care at
a state referral hospital in Vitória, Espírito Santo, Brazil.
The study population was monitored over a period of
eleven years.Methods
A retrospective cohort study was conducted with verti-
cally HIV-infected children and adolescents receiving
care at the Nossa Senhora da Glória Pediatric State Hos-
pital and followed up at the Infectious Disease and AIDS
Pediatric Care Service in Vitória, Espírito Santo, Brazil.
The study population consisted of all the patients with
vertically transmitted AIDS receiving care at this unit
between January 2001 and December 2011.
The mortality data on the patients being monitored
and the basic cause of death were obtained from the
medical records and directly from the death certificate.
For patients who were lost to follow-up or who had been
transferred to another service, data were obtained by
consulting the mortality data system for the state of
Espirito Santo during the study period, updated to De-
cember 2012. This database includes the death certifi-
cates collected by the State Health Department with the
specific purpose of providing data of the greatest rele-
vance for defining priorities in programs for the preven-
tion and control of diseases [23].
The data were collected in 2011 and 2012 based on
the patients’ medical records, using a specific standard-
ized form on which the mother’s clinical information
(prenatal care, whether the complete protocol for the
prevention of the vertical transmission of HIV was ap-
plied, i.e. during pregnancy, delivery and in the newborn
infant), aspects related to the family, demographic data
on the child and its diagnostic status were recorded. In
addition, data were collected on the quantification of
baseline HIV plasma viral load, nadir CD4+ and CD8 T-
cell count. Initiation of HAART before 6 months of age
and for more than three months, as well as the presence
of comorbidities classified according to the clinical clas-
sification categories defined by the Centers for Disease
Control and Prevention (CDC, 1994) and the presence
of congenital syphilis were also recorded [24].
With respect to the laboratory tests performed, between
2001 and 2008 viral load was quantified by reverse-
transcription polymerase chain reaction assays (RT-PCR)
using Cobas Amplicor® HIV-I Monitor™ test, version 1.5
(Roche Molecular Systems, Inc. Branchburg, NJ, USA),
with a detection limit of 400 copies/mL. From 2009 on-
wards, the kit used was the b-DNA Versant® HIV-1 RNA
3.0 assay (Siemens, NY, USA), with a detection limit of 50
copies/mL. CD4+ T-cell count was measured by flow
cytometry, using immunophenotyping (BD Biosciences,
CA, USA). The Infectious Diseases Unit of the Federal
University of Espírito Santo performed both tests using
kits supplied by the Brazilian Ministry of Health.
The data were included in a spreadsheet using the
Statistical Package for the Social Sciences statistical soft-
ware program, version 18.0 for Windows (SPSS, Inc.,
Chicago, IL, USA). To evaluate mortality (the endpoint),
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centages of the qualitative variables were calculated for
each group. The chi-square test or Fisher’s exact test was
used as appropriate to measure the association between
the qualitative variables and the endpoint. In the case of
the quantitative variables, the means, medians, standard
deviations and interquartile ranges were calculated and
the Mann–Whitney non-parametric test was applied. For
the study variables that were found to be statistically sig-
nificant at a level of 10% in the chi-square test, logistic
regression analysis was used to calculate the crude and
adjusted odds ratios. Logistic regression analysis was
performed in blocks, with the first block consisting of the
sociodemographic and clinical variables and the second
block the comorbidities. The forward stepwise likelihood
ratio, in which the variables are included one by one to
test for significance, was used to establish which of the
variables were to be entered into the model. Only the
adjusted odds ratios of the variables that remained in the
final model will be presented. Significance level was estab-
lished at 5%.
The internal review board of the Nossa Senhora da
Glória State Pediatric Hospital (Reference Number
50/2009) approved this study. The data collected from
the charts were used exclusively for the purposes of this
study. The patients’ identity was maintained confidential
through the use of codes.
Consent
Written informed consent was obtained from the pa-
tient’s guardian/parent/next of kin for the publication of
this report and any accompanying images.
Results
A total of 177 children and adolescents with vertically






2001 2002 2003 2004 2005 20
Alive
Figure 1 Sample distribution, total number of children and adolescen
the year of diagnosis of children and adolescents with vertically trans
State Pediatric Hospital between 2001 and 2011 (n = 177), Vitoria, Brazil.seven were female (54.8%) and the median age of the
patients at admission to the study was 30 months (inter-
quartile range [IQR]: 5–72 months). With respect to
ethnicity, the majority was mulatto (n = 111; 62.7%) and
124 (70.0%) were from the metropolitan region of
Vitoria.
The total time of follow-up of the patients evaluated
in this study was 11 years, with a median time of 5 years
(IQR: 2–8 years). Of the 33 children who initiated anti-
retroviral therapy (ART) in 2001 and 2002, 25 are still
alive and were monitored throughout the entire study
duration. Two patients have never initiated HAART. At
the end of the study, 132 patients (74.6%) remained in
follow-up, 11 (6.2%) had been transferred to another
service and 8 (4.5%) were lost to follow-up. Twenty-six
patients (14,7%) had died (Figure 1).
The majority of these children were under three years of
age (16/26; 61.5%) at the time of death, with deaths occur-
ring throughout the entire decade evaluated. Figure 1
shows the distribution of the surviving and deceased
patients according to the year of their diagnosis. Note a
reduction in the number of cases over time and the even
distribution of the deaths over the years of the study. The
mean survival of the children included in the study was
10.20 years (95% CI: 9.62–10.79 years).
The majority of the patients who died were less than
one year old when they were admitted to the clinic and
most had advanced clinical and immunological disease
(76.9%; 20/26). The majority had moderate/severe
anemia (median hemoglobin level 9.7; IQR: 8.4 – 11.1)
and had been on ART for more than three months (17/
24; 71%). At admission to the specialist care service,
the majority (20/26; 76.9%) of the patients who died
were classified as clinical stage 4 according to the
WHO staging system: the most severe stage and a pre-
dictor of mortality (p = 0.005). In 68.0% of the children06 2007 2008 2009 2010 2011
Dead
ts and total number of deaths in absolute numbers according to
mitted AIDS. Infectious Diseases and AIDS Pediatric Care Clinic of the
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having become ill.
The association between the qualitative variables and
the patients’ final status (alive/dead) is shown in Table 1.
In relation to the endpoint (death), a statistically signifi-
cant (p < 0.05) association was found with: age < 1 year at
the time of admission to the service, the use of ART for
more than three months, having advanced clinical and
immunological disease, CD4+ percentage <15% and HIV
plasma viral load ≥ 100,000 copies/ml, in addition to
diagnosis having been made as a result of the patient
becoming ill. Initiating ART before six months of age was
associated with being alive (OR: 2.86; 95% CI: 1.12 – 7.25;
p = 0.027).
For the quantitative variables nadir CD4+ and CD8 T-cell
count, the means, medians, standard deviations and inter-
quartile ranges were calculated and the Mann–Whitney
non-parametric test was performed. No statistically signifi-
cant differences were found between the patients who
survived and those who died with respect to nadir T-cell
count, as shown in Table 2. In the 26 patients who died,
mean CD4+ count was 610.0 (IQR: 324 – 1222) and CD8
T-cell count was 1,152 (IQR: 778 – 2,394).
Table 3 shows the association between comorbidities
and death. Statistically significant correlations with the
endpoint were found for: Pneumocystis jiroveci pneumo-
nia, thrombocytopenia, severe recurrent bacterial infec-
tions, any type of candidiasis, chronic anemia, HIV/
hepatitis co-infection, wasting syndrome, extrapulmon-
ary cryptococcosis, kidney disorders, tuberculosis, and
lymphadenopathy > 0.5 cm at more than two sites.
According to the medical records, the causes of death
(grouped according to diagnosis) were: severe bacterial
infection (57.0%), opportunistic infections (33.3%), acute
kidney failure (4.7%) and Burkitt’s lymphoma (4.7%). In
five cases, the cause of death was unknown.
In the final regression model, the variables indicated as
being most strongly associated with death were: being
under one year old (adjusted OR: 10.20; 95% CI: 1.99 –
52.21; p = 0.005), P. jiroveci pneumonia (OR: 7.26; 95% CI:
1.62 – 32.54; p = 0.010), CD4+ T-cell count < 15% (OR:
4.25; 95% CI: 1.38 – 13.06; p = 0.012), chronic anemia
(OR = 6.73; 95%CI: 1.53 – 29.64; p = 0.012), advanced clin-
ical and immunological disease (OR = 4.41; 95% CI: 1.68 –
11.61; p = 0.003), severe recurrent bacterial infections
(OR: 4.27; 95% CI: 1.61 – 11.32; p = 0.003) and tubercu-
losis (OR: 2.90; 95% CI: 1.07 – 7.92; p = 0.037) as well
as extrapulmonary cryptococcosis (OR = 12.87; 95% CI:
1.12 – 147.70; p = 0.04) and kidney disorders (OR =
12.61; 95% CI: 1.10 – 144.72; p = 0.042) (Table 4).
Discussion
The accumulated mortality rate was almost 15% for this
cohort over the 11-year period of evaluation at a statereferral hospital in Vitória, Espírito Santo, Brazil. This
rate is higher than that found in a cohort of 320 children
and adolescents in Belo Horizonte, Minas Gerais, Brazil
(9.7%) and also higher than the rate of 12.1% reported in a
study on the impact of HAART, opportunistic infections,
hospitalizations and mortality in 371 children and adoles-
cents in Belo Horizonte [8,9]. Nevertheless, this rate was
lower than that of 26.9% found in the US Perinatal AIDS
Collaborative Transmission Study (1986–2004) [4].
Analysis of the US perinatal HIV cohort showed a trend
towards a gradual decline in mortality that corresponded
to the advancements in antiretroviral therapeutics, with
the mean annual mortality rate decreasing significantly be-
tween the three therapeutic eras. There was a reduction of
over 60% in the number of deaths between the era in
which no therapy or only monotherapy was available and
the era of monotherapy or dual-combination therapy, and
a reduction of 90% with the triple-combination therapy/
antiretroviral therapy compared to the era of monother-
apy/dual-combination antiretroviral therapy, with a not-
able increase in the proportion of deaths from causes
unassociated with opportunistic infections [4]. On the
contrary, in the present study, the principal grouped
cause of death was severe bacterial infections, probably
due to the differences between industrialized countries
and resource-limited countries. As also reported in the
study from Belo Horizonte, the two principal causes of
death were pneumonia and sepsis [8]. In a cohort study
conducted with 586 HIV-infected children in Thailand
who initiated use of antiretroviral therapy, all the 42
deaths that occurred were attributed to infection [25].
In the present study, it is clear that the deaths were
evenly distributed throughout the years evaluated (2001–
2011). In 2011 in Brazil, the standardized coefficient of
mortality in AIDS patients was 5.6 per 100,000 inhabi-
tants; however, distribution varied over time [26].
When logistic regression analysis was used to adjust the
OR for the risk of death in children and adolescents with
vertically acquired AIDS in Vitória, a statistically signifi-
cant association was found between death and the child
being under one year of age at admission to the service
(65.4%). At the time of death, the majority of the children
were under three years of age. In the US cohort study, of
the 364 HIV-infected children, 98 deaths occurred. Of
these, 81% were under three years of age and 62% were
under two years of age. The majority (84%) was born prior
to 1994, three years before protease inhibitors became
available as antiretroviral therapy (triple-combination
therapy). Similar findings were reported in the French
cohort of 348 HIV-infected children. Forty-seven of these
children (13.5%) died before reaching their second birth-
day and 58 (17%) prior to their third. Most of the deaths
occurred before 1996 [27]. In the present study, the cohort
was followed throughout the decade of 2000, with the
Table 1 Association between demographic and clinical variables, treatment, maternal HIV status, HIV plasma viral load
and CD4+ T-cell count and mortality in children and adolescents with vertically transmitted AIDS
Current Status*
Variable Total Alive Dead p-value**
N % N % N %
Sex
Male 80 45 71 47 9 35 0.240
Female 97 55 80 53 17 65
Age-group at admission
<1 year 60 34 43 28 17 65 0.001
≥1 year 117 66 108 72 9 35
Skin color
White 33 19 30 20 3 12 0.314
Other 144 81 121 80 23 88
Place of residence
Metropolitan region 123 69 107 71 16 62 0.340
Other 54 31 44 29 10 38
ART initiated before 6 months of age
Yes 34 20 25 17 9 38 0.023
No 134 80 119 83 15 63
More than three months of ART
Yes 161 96 144 100 17 71 0.001
No 7 4 0 0 7 29
Severe immune impairment
Yes 85 48 65 43 20 77 0.001
No 92 52 86 57 6 23
CD4+ percentage
>25% 67 38 62 41 5 20 0.024
15–24% 61 35 53 35 8 32
<15% 47 27 35 23 12 48
Baseline HIV viral load
≥ 100,000 102 58 80 53 22 88 0.001
<100,000 73 42 70 47 3 12
Mother had prenatal care
Yes 95 55 81 55 14 56 0.933
No 77 45 66 45 11 44
Mother’s diagnosis
Prior to or during delivery 56 32 48 32 8 32 0.983
Following delivery 118 68 101 68 17 68
Mother received prophylactic treatment
Yes 39 22 32 21 7 28 0.469
No 135 78 117 79 18 72
During pregnancy
Yes 25 14 20 13 5 20 0.386
No 149 86 129 87 20 80
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Table 1 Association between demographic and clinical variables, treatment, maternal HIV status, HIV plasma viral load
and CD4+ T-cell count and mortality in children and adolescents with vertically transmitted AIDS (Continued)
At delivery
Yes 33 19 28 19 5 21 0.813
No 140 81 121 81 19 79
Infant received prophylactic treatment
Yes 38 22 31 21 7 29 0.359
No 135 78 118 79 17 71
Whether the entire ACTG 076 protocol was implemented
Yes 12 7 10 7 2 8 0.807
No 163 93 140 93 23 92
Type of delivery
Vaginal 105 72 86 70 19 83 0.233
Cesarean 40 28 36 30 4 17
Breastfeeding
Yes 113 73 98 75 15 63 0.212
No 42 27 33 25 9 38
Category of exposure of mother
Injectable drug user 16 11 14 10 2 12 0.869
Sexual 134 88 119 88 15 88
Transfusion 2 1 2 1 0 0
How diagnosis of case was made
Mother with AIDS became pregnant 7 4 4 3 3 12 0.003
Mother during prenatal care 30 17 30 20 0 0
Mother at or after delivery, or father 61 35 56 38 5 20
When the child became ill 75 43 58 39 17 68
When a sibling was diagnosed 1 1 1 1 0 0
Current care-giver
Mother, father or other relative 149 85 126 84 23 92 0.298
Adopted or in an institution 26 15 24 16 2 8
BMI adequate for age
Yes 26 34 23 38 3 18 0.111
No 51 66 37 62 14 82
*There are missing values in some variables. **p-value of the chi-square test. The numbers in boldface highlight the statistical significance.
Infectious Diseases and AIDS Pediatric Care Clinic of the State Pediatric Hospital between 2001 and 2011 (n = 177), Vitoria, Brazil.
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and, later, triple-combination therapy in accordance with
the Ministry of Health’s recommendations for the treat-
ment of HIV-infected children.
The mean survival time of the children in this study
was 10 years. Observational studies and international
cohorts conducted to study survival in children with
AIDS have reported a significant improvement, with re-
sults that are similar to those found in a Brazilian cohort
showing an increase in the probability of survival of chil-
dren with AIDS [4,11,25].
When the characteristics of the children and adolescents
with AIDS acquired exclusively by vertical transmission,which represent 90% of the cases seen at this service, were
evaluated, it was found that the majority had not been ex-
posed to perinatal prophylaxis. This finding is in line with
the statistics available on children with AIDS in Brazil. Of
the 15,775 cases of AIDS in children under 13 years of
age notified in the country up to 2011, 14,329 (90.8%)
occurred by vertical transmission [26].
The main limitation of this study was the retrospective
design. We could not recover some missing information.
To minimize the limitations inherent to the design of
the present study, a standardized form was used to col-
lect the data. In addition, all the forms were reviewed
and if any social data deemed important for the study
Table 2 Association between death and nadir CD4+ and
CD8 T-cell count in vertically HIV-infected children and
adolescents
Variable Statistics Current status p-value*
Alive Dead
Median 877.0 610.0 0.158
Nadir CD4+ T-cell count Maximum 4556.0 5189.0
Minimum 8.0 44.0
25th percentile 520.0 324.0
75th percentile 1352.0 1222.0
Median 1331 1152 0.538
Nadir CD8 T-cell count Maximum 7318 6784
Minimum 58 408
25th percentile 845 778
75th percentile 2042 2394
*Mann–Whitney non-parametric test.
Infectious Diseases and AIDS Pediatric Care Clinic of the Pediatric Hospital
between 2001 and 2011 (n = 177), Vitoria, Brazil.
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or caregivers.
At the time of admission to the service, most of the chil-
dren who died in the present study were already classified
as WHO stage 4, the most severe stage of the disease ac-
cording to clinical and immunological criteria, this being a
predictor of death (p = 0.005). In addition, in the majority
of cases, diagnosis was reached as the result of the devel-
opment of diseases that define AIDS, indicating that diag-
nosis of the HIV infection was late. The cohort study
in Belo Horizonte, in which the prognostic value of the
WHO’s clinical stage classification was evaluated in 335
HIV-infected children and adolescents, showed that pa-
tients at a risk of progression to AIDS or death were at
clinical stage 3 and 4, with the risk of a poorer prognosis
being greater in those at clinical stage 4. When controlled
for CD4 count and viral load in a multivariate analysis,
stage 4 remained an important predictor of death [22]. In
a study conducted in Uganda in which 23,367 patients in-
cluding 810 children and 575 adolescents were analyzed, a
statistically significant association was found between
mortality and advanced clinical stages of the disease ac-
cording to the WHO classification system. The crude
mortality rate was lower in children than in adolescents, a
vulnerable and more complex group [28].
In agreement with the findings of other studies, the use
of ART for more than three months, advanced clinical and
immunological disease, percentage of CD4+ T-cell
count < 15%, HIV plasma viral load ≥ 100,000 copies/ml
and diagnosis of the case as a result of the patient’s
illness were independent predictive factors of mortality.
The study conducted with children in Belo Horizonte
reported similar findings, with patients in whom CD4+
T-cell count was < 15% and viral load was 5 log beingassociated with a higher rate of adverse clinical pro-
gression and a greater risk of death [8]. In a double-
blind, randomized, placebo-controlled study involving
566 symptomatic, HIV-infected infants and children in
the United States aged between three months and eight-
een years, Palumbo et al. evaluated the risk of progression
of the disease based on baseline RNA levels and CD4+ T-
cell count and showed that a combination of these two
markers is capable of predicting progression of the disease
and death. Furthermore, when treating HIV-infected chil-
dren, suppression of viral replication enables the immune
system to be maintained intact [29]. Monfenso et al.
showed that viral loads of 100,000 copies and CD4+ T-cell
counts <15% in children under 30 months old were inde-
pendent predictors of an increased risk of clinical progres-
sion of the disease and death [30]. The longitudinal study,
Cross Continents Collaboration for Kids (3Cs4kids), con-
ducted with children over 12 months of age in Africa,
showed that both CD4 percentage and absolute CD4 cell
count were the greatest predictors of mortality. Further-
more, this study showed that mortality is high in under-
weight and anemic children of less than two years of age
irrespective of their immunological status [21].
In agreement with those investigators, the results of the
present study showed that moderate anemia was also sig-
nificantly associated with mortality. On the other hand, no
statistically significant association was found with respect
to BMI for age. In the study conducted in Thailand, CD4+
percentage was independently associated with mortality,
with an increased risk of 67% being reported for a de-
crease of 5% in nadir CD4+ T-cell count. Nadir CD4+ T-
cell count, cachexia and hemoglobin levels were associ-
ated with a high risk of mortality even after the first year
of antiretroviral therapy [25].
In the present study, the fact of having initiated ART
prior to six months of life, having been diagnosed early
and having initiated treatment promptly were found to
be protective factors. These findings are in agreement
with the results of the US study, in which HIV-infected
children receiving ART in the first six months of life had
a 94% likelihood of survival at 6 years of age [4]. The
benefit of initiating antiretroviral therapy before reaching
three months of life to avoid progression to AIDS and
death in HIV-infected children has been shown in a ran-
domized clinical study conducted in South Africa [18].
Furthermore, the European Collaborative Study con-
cluded that initiating antiretroviral therapy prior to three
months of life has a dramatic effect in reducing progres-
sion to AIDS and death in high-income countries [14].
In these eleven years of follow-up, loss to follow-up was
only 4.5%, lower than that reported in other studies such
as the 10.9% in the study conducted in Belo Horizonte
and the 9.5% reported for the study carried out in France
with perinatally-infected HIV-infected adolescents [8,27].
Table 3 Association between comorbidity and death in vertically HIV-infected children and adolescents presented in
order of statistical significance according to the chi-square test
Current Status
Comorbidity Alive Dead p-value
N % N %
P. jiroveci Pneumonia 21 14 13 54 0.000
Thrombocytopenia 15 10 9 36 0.002
Severe recurrent bacterial infections 63 43 19 76 0.002
Candidiasis – any type 45 30 15 60 0.004
Chronic anemia 94 63 23 92 0.004
HIV/Hepatitis co-infection 22 15 10 40 0.009
Wasting syndrome 29 19 10 40 0.023
Extrapulmonary cryptococcosis 1 1 2 8 0.054
Kidney disorders 1 1 2 8 0.056
Tuberculosis 17 11 7 27 0.056
Lymphadenopathy > 0.5 cm at more than two sites 106 71 13 52 0.057
First episode of pneumonia, bacteremia or sepsis 91 61 20 80 0.074
Prolonged diarrhea or gastroenteritis 57 38 14 56 0.095
HIV encephalopathy 19 13 6 24 0.138
Cerebral toxoplasmosis 1 1 1 4 0.148
Non-Hodgkin’s lymphoma 1 1 1 4 0.150
HIV-associated myocarditis 3 2 2 8 0.152
Splenomegaly 92 62 19 76 0.170
Persistent fever 46 31 11 44 0.196
Chronic parotitis 22 15 1 4 0.205
Lymphocytic interstitial pneumonia 31 21 3 12 0.304
Congenital syphilis 5 3 0 0 0.351
Any helminth or protozoan infection 14 9 1 4 0.374
Mucocutaneous herpes simplex 4 3 0 0 0.404
Dyslipidemia 11 7 1 4 0.532
Isosporiasis 2 1 0 0 0.556
Hepatomegaly 120 81 22 88 0.577
Dermatitis 63 42 12 48 0.593
Urinary infection 30 20 6 24 0.659
Progressive multifocal leukoencephalopathy 1 1 0 0 0.681
Disseminated mycobacteriosis 1 1 0 0 0.681
Acute otitis media or recurrent sinusitis 84 56 13 52 0.709
Cytomegalovirus infection 14 9 3 12 0.725
Pancreatitis associated with HIV infection 8 5 1 4 0.775
Congenital or acquired toxoplasmosis 10 7 2 8 0.902
Varicella or Herpes zoster 43 29 7 28 0.930
Gingivostomatitis or recurrent herpes 5 3 0 0 1
Cryptosporidiosis 1 1 0 0 1
Infectious Diseases and AIDS Pediatric Care Clinic of the State Pediatric Hospital between 2001 and 2011 (n = 177), Vitoria, Brazil.
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Table 4 Regression analysis for the risk of death in vertically HIV-infected children and adolescents
Variable Crude OR Adjusted OR*
p-value OR 95% CI p-value OR 95% CI
Age-group at admission to service
< 1 year 0.001 4.74 1.96 11.46 0.005 10.20 1.99 52.21
≥ 1 year 1.00 1.00
ART initiated before 6 months of age
Yes 0.027 2.86 1.12 7.25 0.860 0.86 0.16 4.63
No 1.00 1.00
Use of ART >3 months
Yes a a a a a a a a
No 1.00
Advanced clinical and immunological disease (B3C123)
Yes 0.003 4.41 1.68 11.61
No 1.00
Percentage CD4+ T-cell count
>25% 1.00 1.00
15–24% 0.296 1.87 0.58 6.07 0.244 2.62 0.52 13.22
<15% 0.012 4.25 1.38 13.06 0.107 5.06 0.71 36.29
Baseline HIV viral load
≥ 100,000 0.004 6.42 1.84 22.36 0.115 3.31 0.75 14.71
<100,000 1.00 1.00
Origin of diagnosis
Mother had AIDS when she became pregnant 1.00 1.00
Mother during prenatal care a a a a a a a a
Mother during or following delivery, or father 0.017 0.12 0.02 0.69 0.108 0.13 0.01 1.57
When the child became ill 0.247 0.39 0.08 1.92 0.532 0.49 0.05 4.64
At diagnosis of a sibling a a a a a a a a
Comorbidities
P. jiroveci pneumonia 0.001 7.20 2.85 18.19 0.010 7.26 1.62 32.54
Thrombocytopenia 0.001 5.02 1.89 13.33
Severe recurrent bacterial infections 0.003 4.27 1.61 11.32
Candidiasis - any type 0.005 3.47 1.45 8.30
Chronic anemia 0.012 6.73 1.53 29.64
Hepatitis/ HIV 0.004 3.85 1.53 9.65
Wasting syndrome 0.027 2.76 1.12 6.77
Extrapulmonary cryptococcosis 0.040 12.87 1.12 147.70
Kidney disorders 0.042 12.61 1.10 144.72 0.020 50.92 1.84 1411.87**
Tuberculosis 0.037 2.90 1.07 7.92
Lymphadenopathy >0.5 cm at more than two sites 0.061 0.44 0.19 1.04
Severe recurrent bacterial infection 0.082 2.51 0.89 7.05
Prolonged diarrhea or gastroenteritis 0.099 2.05 0.87 4.84
a: not calculated, no cases.
*Analysis performed with data from 153 cases (86.4% of the sample).
**This value is high due to problems in calculating the confidence interval, since there were few cases of this variable.
The numbers in boldface highlight the statistical significance.
Infectious Diseases and AIDS Pediatric Care Clinic of the State Pediatric Hospital between 2001 and 2011 (n = 177), Vitoria, Brazil.
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was five years. Of the 33 children who initiated antiretro-
viral treatment in 2001 and 2002, 25 remained alive and in
follow-up at the end of these eleven years. The median
age at admission to the service was 30 months, character-
izing late diagnosis of the HIV infection, a characteristic
that has been reported in other Brazilian studies [15,31].
Unlike the findings of the present study in which diagnosis
and treatment were late, in the cohort study conducted
with perinatally HIV-infected French adolescents’ diagno-
sis of the HIV infection was made at an early stage and
most of the children initiated treatment prior to nine
months of life [27].
Conclusions
In this particular Brazilian state, dozens of children have
been diagnosed with HIV infection at a late stage, in-
creasing their risk of progression to AIDS and death due
to a lack of timely treatment. Mortality trends in HIV-
infected children remained constant over the study
period, with a decrease in the final two years. Bacterial
infections remain the principal cause of death. There-
fore, improving prenatal care and pediatric follow-up in
an effort to diagnose vertically infected children as early
as possible and treating malnutrition and anemia should
be an integrated part of the healthcare provided to the
child with AIDS, an action that may reduce mortality in
these children.
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